Amneal Pharmaceuticals(US:AMRX) ZACKS·2026-02-05 15:40Core Insights - The article emphasizes the importance of the Zacks Rank system, which focuses on earnings estimates and revisions to identify strong stocks [1] - Value investing is highlighted as a popular strategy for finding undervalued companies based on fundamental analysis [2] Company Analysis: Amneal Pharmaceuticals (AMRX) - Amneal Pharmaceuticals is currently rated with a Zacks Rank 2 (Buy) and has an A grade for Value, making it a notable stock for value investors [3] - The company has a Price-to-Sales (P/S) ratio of 1.55, significantly lower than the industry average of 4.46, indicating potential undervaluation [4] - Amneal's Price-to-Cash Flow (P/CF) ratio stands at 10.89, compared to the industry average of 14.01, further supporting the notion of being undervalued [5] - Over the past 12 months, AMRX's P/CF has fluctuated between a high of 61.60 and a low of 8.57, with a median of 16.33, showcasing its cash flow performance [5] - Overall, the metrics suggest that Amneal Pharmaceuticals is likely undervalued, and its strong earnings outlook positions it as one of the market's strongest value stocks [6]